This company listing is no longer active
OKYO Aktienübersicht
A clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Belohnungen
Risikoanalyse
+ 2 mehr Risiken
OKYO Pharma Limited Wettbewerber
Preisentwicklung & Leistung
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.91 |
| 52 Week High | UK£3.90 |
| 52 Week Low | UK£0.88 |
| Beta | -0.062 |
| 1 Month Change | -9.68% |
| 3 Month Change | -65.69% |
| 1 Year Change | -63.64% |
| 3 Year Change | -45.10% |
| 5 Year Change | n/a |
| Change since IPO | -98.13% |
Aktuelle Nachrichten und Updates
Recent updates
Can OKYO Pharma (LON:OKYO) Afford To Invest In Growth?
Nov 26
Is OKYO Pharma (LON:OKYO) In A Good Position To Deliver On Growth Plans?
Jan 27Here's Why We're Not At All Concerned With OKYO Pharma's (LON:OKYO) Cash Burn Situation
Sep 22We Think OKYO Pharma (LON:OKYO) Can Easily Afford To Drive Business Growth
Mar 17We're Interested To See How OKYO Pharma (LON:OKYO) Uses Its Cash Hoard To Grow
Dec 02Aktionärsrenditen
| OKYO | GB Biotechs | GB Markt | |
|---|---|---|---|
| 7D | -31.7% | -3.4% | -1.4% |
| 1Y | -63.6% | -28.0% | 4.4% |
Rendite im Vergleich zur Industrie: OKYO underperformed the UK Biotechs industry which returned -16.5% over the past year.
Rendite vs. Markt: OKYO underperformed the UK Market which returned -2.2% over the past year.
Preisvolatilität
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 18.1% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.2% |
| 10% least volatile stocks in GB Market | 2.8% |
Stabiler Aktienkurs: OKYO's share price has been volatile over the past 3 months.
Volatilität im Zeitverlauf: OKYO's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of UK stocks.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Gary Jacob | www.okyopharma.com |
OKYO Pharma Limited's Grundlagenzusammenfassung
| OKYO grundlegende Statistiken | |
|---|---|
| Marktanteil | UK£23.22m |
| Gewinn(TTM) | -UK£6.70m |
| Umsatz(TTM) | n/a |
0.0x
Kurs-Umsatz-Verhältnis-3.5x
Kurs-Gewinn-VerhältnisIst OKYO zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| OKYO Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | UK£0 |
| Kosten der Einnahmen | UK£4.39m |
| Bruttogewinn | -UK£4.39m |
| Sonstige Ausgaben | UK£2.31m |
| Umsatz | -UK£6.70m |
Zuletzt gemeldete Gewinne
Sep 30, 2022
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.26 |
| Bruttomarge | 0.00% |
| Nettogewinnspanne | 0.00% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich OKYO auf lange Sicht entwickelt?
Historische Performance und Vergleiche